In July of 2016, the University of Michigan Board of Regents approved the establishment of the University of Michigan Health System (UMHS) Board to advise both the Board of Regents and UMHS leadership on the strategic direction and operating performance of the UMHS. Reporting to the Board of Regents and comprised of both internal and external leaders in healthcare, the UMHS Board exercises duties through recommendations to the Executive Vice President of Medical Affairs and Dean of the University of Michigan Medical School, the President of the University and the University of Michigan Board of Regents.
- January 22, 2021
- April 23, 2021
- July 23, 2021
- October 29, 2021
- January 28, 2022
- April 22, 2022
- July 22, 2022
- October 28, 2022
UMHS Board Members
Dr. Mark S. Schlissel is the 14th president of the University of Michigan and the first physician-scientist to lead the institution. He became president in July 2014, after serving as provost of Brown University. A graduate of Princeton University (A.B., summa cum laude, 1979, Biochemical Sciences), he earned both M.D. and Ph.D. degrees at the Johns Hopkins University School of Medicine (1986, Physiological Chemistry), afterwards completing his residency training in internal medicine at Hopkins Hospital and conducted postdoctoral research as a Bristol-Myers Cancer Research Fellow at the Massachusetts Institute of Technology’s Whitehead Institute.
President Schlissel began his career as a faculty member at the Johns Hopkins University School of Medicine in 1991, later moving to the Department of Molecular and Cell Biology at the University of California–Berkeley in 1999 as associate professor, advancing to full professor and serving as vice department chair in 2002. He was UC-Berkeley’s dean of biological sciences in the College of Letters & Science and held the C.H. Li Chair in Biochemistry until his appointment as Brown’s provost in 2011.
Marshall S. Runge, M.D., Ph.D., is executive vice president for Medical Affairs at the University of Michigan, Dean of the Medical School, and CEO of Michigan Medicine. Prior to joining the University of Michigan in March 2015, he was executive dean and chair of the Department of Medicine at the UNC School of Medicine. He was also principal investigator and director of the North Carolina Translational and Clinical Sciences (NC TraCS) Institute at UNC-Chapel Hill. Before joining the UNC faculty in 2000, Dr. Runge held the John Sealy Distinguished Chair in Internal Medicine and was director of the Division of Cardiology and the Sealy Center for Molecular Cardiology at the University of Texas Medical Branch at Galveston.
Dr. Runge earned his doctorate in molecular biology at Vanderbilt University and his medical degree from Johns Hopkins School of Medicine, where he also completed a residency in internal medicine. He was a cardiology fellow and faculty member at Harvard’s Massachusetts General Hospital before joining Emory University as an associate professor of medicine in 1989.
Dr. David Miller has served as President, University of Michigan Health System and Executive Vice Dean for Clinical Affairs, University of Michigan Medical School since January 1, 2021. University of Michigan Health System is composed of C.S. Mott Children's Hospital, the Von Voigtlander Women's Hospital, University Hospital, Frankel Cardiovascular Center, and the University of Michigan Medical Group, including 2,000 physicians, and 140 clinics at 40 sites throughout Southeastern Michigan. In this role, Dr. Miller oversees all activities of the health system that serves patients from throughout Michigan and around the world.
Dr. Miller served as Chief Clinical Officer for University Hospital and the Frankel Cardiovascular Center from 2018-2020. Working in partnership with the Chief Operating Officer and Chief Nursing Officer, Dr. Miller provided clinical operational leadership to ensure quality and safety in clinical programs and patient care, improve patient experience, enhance staff engagement, and optimize capacity management within the two adult hospitals.
Dr. Miller is a Professor in the Department of Urology and maintains a clinical practice that focuses on the diagnosis and management of patients with prostate cancer.
In addition to his clinical practice, Dr. Miller served as Director of the Michigan Urological Surgery Improvement Collaborative (MUSIC) 2011 through 2020. Funded by Blue Cross Blue Shield of Michigan (BCBSM), MUSIC is a consortium of more than 40 urology practices aiming to improve the quality and cost-efficiency of urological care in the state of Michigan.
Dr. Miller also has a broad background in health services research, including substantial experience using claims data and formal training in the advanced statistical methods used in observational data analyses. With prior funding from the Agency for Healthcare Research & Quality and the National Cancer Institute, Dr. Miller's empirical research agenda focused on comparative effectiveness research, physician-led collaborative quality improvement, and understanding the relationship between physician organizations, integrated delivery systems, and the quality and cost of specialty care.
Kedrick D. Adkins, Jr., is the former Chief Financial Officer for the Mayo Clinic, where he was directly responsible for Contracting and Payer Relations; Enterprise Revenue Cycle; Finance in Arizona, Florida and the Midwest; Financial and Accounting Services; Mayo Clinic Ventures; Supply Chain Management; and Treasury. Prior to the Mayo Clinic, Kedrick served seven years as president of Integrated Services for Trinity Health, providing oversight of the complete span of finance, treasury, information technology, supply chain management, operations, performance leadership, insurance and risk management, integration services, and payer and product innovation across the 10 states in which Trinity Health operated. Prior to that, Kedrick spent 30 years at Accenture, a global management consulting firm, where he held roles as global managing partner for the Health Care Practice, global chief diversity officer and country managing director, U.S. Operations.
Kedrick holds an MBA in Finance and Accounting and a B.S. in Industrial and Operations Engineering from the University of Michigan, Ann Arbor.
Dee Fenner is the Chair of the Department of Obstetrics and Gynecology and Bates Professor of Diseases of Women and Children at the University of Michigan. She holds a joint appointment as Professor of Urology. As a Missouri native, she attended undergraduate and medical school at the University of Missouri – Columbia. She completed a residency in Obstetrics and Gynecology at the University of Michigan followed by a fellowship in Pelvic Reconstructive Surgery and Urogynecology at the Mayo Clinic-Scottsdale. In 2001, Dr. Fenner returned to the University of Michigan where she continues her work in female pelvic floor dysfunction and medical education.
The University of Michigan Board of Regents appointed Kevin Hegarty executive vice president and chief financial officer effective April 6, 2015. Prior to joining the University of Michigan, Mr. Hegarty served higher education as the vice president and chief financial officer at the University of Texas at Austin from 2001 – 2015. He held senior leadership roles at: Dell Inc., vice president and chief financial officer, 2000 – 2001; vice president and corporate comptroller, 1997 – 2000; Associates First Capital Corporation/Ford, senior vice president and company comptroller, 1990-1997; Trammell Crow Company, senior group financial manager, 1984 – 1990; and PricewaterhouseCoopers, senior auditor, 1979-1984.
Mr. Hegarty received his MA in Professional Accounting from the University of Texas at Austin in 1979 and his BBA in Accounting from the University of Texas at Austin in 1977.
Patricia D. Hurn is the current dean of the University of Michigan School of Nursing. Previously, she served as a vice chancellor for research and innovation at the University of Texas System. Dr. Hurn has received more than $20 million in NIH funding as a principal investigator. She is a global leader in research focused on understanding the cellular and molecular basis of gender differences in brain injuries, as well as stroke and other neurological conditions. Much of Dr. Hurn’s work as a researcher and health system executive has included a strong emphasis on trans-disciplinarity and interprofessional initiatives. Her leadership efforts focus on collaborative bio-health research models, science education innovation and research technologies.
Dr. Hurn earned her BSN at the University of Florida, MN at the University of Washington, and PhD at Johns Hopkins University.
Dr. Johns currently serves as Professor in the Schools of Medicine and Public Health at Emory University. He is Executive Vice President for Health Affairs Emeritus at Emory University, and President, CEO, and Chairman of the Board Emeritus of Emory Healthcare – positions he held at Emory from 1996 to 2007. He also served as Emory’s Chancellor from 2007 to 2012. Prior to coming to Emory, Dr. Johns was Vice President of the Medical Faculty and Dean of the Johns Hopkins School of Medicine. He also served as interim Executive Vice President for Medical Affairs at the University of Michigan from June 2014 thru February 2015.
Dr. Johns received his bachelor's degree from Wayne State University and graduated with distinction from the University of Michigan Medical School. After completing his residency training in Otolaryngology/Head and Neck Surgery at Michigan, he joined the Medical Corps of the U.S. Army and was assistant chief of the Otolaryngology Service at Walter Reed Army Medical Center. In 1977, he joined the Department of Otolaryngology and Maxillofacial Surgery at the University of Virginia Medical Center, where he rose to the rank of Professor. In 1984, Dr. Johns was recruited to Johns Hopkins as professor and chair of Otolaryngology-Head and Neck Surgery.
Dr. Mark Prince is the Charles J. Krause M.D. Collegiate Professor of Otolaryngology and Chair of the Department of Otolaryngology – Head and Neck Surgery. After completing a degree in chemical engineering at the Technical University of Nova Scotia and earning his Medical Degree at Dalhousie University Medical School in Halifax, Nova Scotia, Dr. Prince went on to serve with the Canadian Armed Forces as a medical officer where he received specialized training in hyperbaric and diving medicine. Dr. Prince returned to Dalhousie University and completed a residency in Otolaryngology Head and Neck Surgery, followed by a two-year fellowship in advanced head and neck oncology and microvascular reconstructive surgery at the University of Michigan.
In 1998, Dr. Prince accepted an appointment at Dalhousie as an Assistant Professor and served as their Otolaryngology Residency Director before joining the University of Michigan faculty in 2000. He also served as the Chief of the Section of Otolaryngology at the Ann Arbor VA Medical Center from 2000 until 2014; he continues to serve there as an active part time staff member.
Dr. Prince is the author of over 160 scientific papers and several book chapters. His research laboratory published the first report of the identification of cancer stem cells in head and neck squamous cell cancer, and continues to conduct research in this exciting field. Dr. Prince also remains actively engaged in resident and medical student education, serving as the Otolaryngology department's Residency Program Director until 2016 and as the Associate Chair for Education from 2009-2016. He also served as the Assistant Dean for Graduate Medical Education until 2018 and continues to co-lead a collaborative education initiative with the ENT department at Komfo Anokye Teaching Hospital in Kumasi Ghana.
Bob is Co-Founder and the Chief Executive Officer of Bright Health, a new health insurance startup serving the Colorado individual marketplace, launching Jan 1 2017. Focused on business development and strategy, Bob draws on more than three decades of experience in healthcare innovation to guide Bright Health on its mission to provide a smarter, more connected healthcare experience that strengthens the relationship between patients their care providers. Before co-founding Bright Health, Bob advised private equity firm and venture capital firms on healthcare. He also served on several for-profit and not-for-profit boards. From 1986 to 2008, Bob led a wide range of initiatives as an executive at UnitedHealth Group, becoming CEO in 2000. Previously, he was one of the first employees at Peak Health Plan before it was acquired by United Healthcare.
Bob earned his bachelors and master’s degrees from the University of Michigan.
Marianne Udow-Phillips is the former Executive Director of the Center for Healthcare Research & Transformation (CHRT) at the University of Michigan, an independent 501(c)(3) impact organization with a mission to advance evidence-based care delivery, improve population health, and expand access to care. Before coming to CHRT, Marianne served as director of the Michigan Department of Human Services from 2004 to 2007, appointed by Governor Jennifer M. Granholm. Marianne came to state service from Blue Cross Blue Shield of Michigan (BCBSM), where she served in a number of leadership roles for over 20 years, most recently as senior vice president of Health Care Products and Provider Services, with responsibility for the BCBSM social mission, health policy, data analysis, and care and network management programs for the traditional and PPO products. She also served as senior vice president and vice president of Plans and Operations for Mercy Alternative and Care Choices.
Marianne holds a master’s degree in Health Services Administration from the U-M School of Public Health; she is a lecturer of public health at the U-M School of Public Health.
Fionnuala Walsh, Ph.D. is a recognized thought leader in the quality industry, often speaking about sustainable, integrated quality systems and the importance of maintaining a quality culture. A native of Ireland, Walsh earned a bachelor's degree and doctoral degree in chemistry from University College Dublin. Prior to her time with Eli Lilly and Company, she was awarded an industrial postdoctoral fellowship with BMS in Puerto Rico and worked at a startup company manufacturing clinic material. She joined Lilly's Kinsale, Ireland, manufacturing site in 1988 as a technical services chemist. After numerous positions there, she moved into a role as global quality leader at the Lilly Corporate Center in Indianapolis in 2002. In January 2003, Walsh was named executive director of quality for U.S. drug product and Lilly Technology Center operations. In July 2005, she was named vice president of global quality operations, and, in June 2007, she was named senior vice president of global quality.
Dr. Tadataka (Tachi) Yamada is a Venture Partner with Frazier Healthcare Partners. He was formerly Executive Vice-President, Chief Medical and Scientific Officer and a Board Member of Takeda Pharmaceuticals. Prior to joining Takeda he served as President of the Bill & Melinda Gates Foundation Global Health Program. In this capacity he oversaw grants totaling over $9 billion in programs directed at applying technologies to address major health challenges of the developing world including TB, HIV, malaria and other infectious diseases, malnutrition and maternal and child health. Before joining the Gates Foundation Dr. Yamada was Chairman, Research and Development and a Member of the Board of Directors of GlaxoSmithKline.
Dr. Yamada was born in Japan, and completed his education in the United States. He graduated from Stanford University with a BA in history and obtained his M.D. from New York University School of Medicine. After completing his internal medicine training at the Medical College of Virginia he became an investigator in the United States Army Medical Research Institute of Infectious Diseases, trained in gastroenterology at the UCLA School of Medicine and assumed his first faculty position there. He later moved to the University of Michigan where he ultimately became Chairman, Department of Internal Medicine and Physician-in-Chief at the University of Michigan Medical Center before joining GlaxoSmithKline.